Skip to main content

Table 4 Overall survival, disease-free survival and breast cancer recurrence in the axilla in the studies comparing ALND and aRT

From: Axillary surgery in women with sentinel node-positive operable breast cancer: a systematic review with meta-analyses

  Overall survival Disease-free survival Breast cancer recurrence in the axilla  
AMAROS ALND: 71/744
aRT: 76/681;
5-year: ALND: 93.3 % (95 % CI 91–95);
aRT: 92.5 % (95 % CI 90–94.4); HR = 1.17 (95 % CI 0.85–1.62), p = 0.34
ALND: 124/744
aRT: 134/681;
5-year: ALND: 86.9 % (95 % CI 84.1–89.3);
aRT: 82.7 % (95 % CI 79.3–85.5); HR = 1.18 (95 % CI 0.93–1.51), p = 0.18
ALND: 4/744
aRT: 7/681;
5-year:
ALND: 0.43 % (95 % CI 0–0.92); aRT: 1.19 % (95 % CI 0.31–2.08)
None of the studies reported local, regional, locoregional or distant breast cancer recurrence
OTOASOR No significant difference, although no overall rates reported ALND: 94.3 %
aRT: 97 %; non-significant
ALND: 0.82 %
aRT: 1.3 %; non-significant
  1. The relative effects of treatments on time-to-event outcomes were reported so that HRs less than 1.0 favour the aRT arm and HRs greater than 1.0 favour the ALND arm
  2. ALND axillary lymph node dissection, aRT axillary radiotherapy